FDA PMA FDA Class 2 Approved (Reclassification) 🇺🇸 United States

Cytomegalovirus (Cmv) Dna Quantitative Assay

PMA: P130027 · Decision Jun 2, 2014
Classifications
1
FEI Numbers
10
Registration Numbers
10

Basic Information

Device Name
Cytomegalovirus (Cmv) Dna Quantitative Assay
Trade Name
ARTUS CMV RGQ MDX KIT
PMA Number
P130027
Device Class
FDA Class 2
Product Code
PAB
Generic Name
Cytomegalovirus (cmv) dna quantitative assay
Regulation Number
866.3180
Medical Specialty
Microbiology
Advisory Committee
Microbiology
Decision
Approved (Reclassification)
Decision Code
APRL
Decision Date
June 2, 2014
Date Received
December 5, 2013
Expedited Review
N
Docket Number
14M-0866

Advisory Committee Statement

APPROVAL FOR THE ARTUS CMV RGQ MDX KIT. THIS DEVICE IS INDICATED FOR: THE ARTUS CMV RGQ MDX KIT IS AN IN VITRO NUCLEIC ACID AMPLIFICATION TEST FOR THE QUANTITATION OF HUMAN CYTOMEGALOVIRUS (CMV) DNA IN HUMAN EDTA PLASMA. THE ARTUS CMV RGQ MDX KIT IS INTENDED FOR USE AS AN AID IN THE MANAGEMENT OF SOLID ORGAN TRANSPLANT PATIENTS WHO ARE UNDERGOING ANTI-CMV THERAPY. THE TEST MEASURES CMV DNA LEVELS IN EDTA PLASMA AND CAN BE USED TO ASSESS CMV VIRAL LOAD RESPONSE TO ANTIVIRAL DRUG THERAPY. THE RESULTS FROM THE ARTUS CMV RGQ MDX KIT MUST BE INTERPRETED WITHIN THE CONTEXT OF ALL RELEVANT CLINICAL AND LABORATORY FINDINGS. THE ARTUS CMV RGQ MDX KIT IS CONFIGURED FOR USE WITH THE EZ1 DSP VIRUS SYSTEM (EZ1 DSP VIRUS KIT AND EZ1 ADVANCED INSTRUMENTS) FOR DNA EXTRACTION AND THE ROTOR-GENE Q MDX INSTRUMENT FOR CMV DNA AMPLIFICATION AND QUANTITATION. THE ARTUS CMV RGQ MDX KIT IS NOT INTENDED FOR USE AS A SCREENING TEST FOR BLOOD OR BLOOD PRODUCTS.

Classifications

This FDA Pre-Market Approval entry is associated with 1 FDA classification via its product code.

Product Code Device Name
PAB Cytomegalovirus (Cmv) Dna Quantitative Assay